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Abstract: Moraxella catarrhalis is a gram negative diplococcus that causes a variety of upper and lower 
respiratory tract infections. Patients with malignant, hematological disorders treated with intensive cytotoxic 
chemotherapy, and recipients of various forms of haematopoietic stem cell transplant receiving 
immunosuppressive agents are at high risk of developing  severe infections and septic complications. Early 
detection of the organism and prompt treatment with appropriate antibiotics provide both resolution of the 
infection and prevention of further consequences. Two patients with haematopoietic stem cell transplant who 
developed pneumonia caused by M. catarrhalis at King Faisal Specialist Hospital and Research Centre in 
Riyadh are reported and the literature is reviewed. To our knowledge, these are the first case reports of M. 
catarrhalis pneumonia in haematopoietic stem cell transplant patients. 
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Introduction 
In spite of the availability of antimicrobial agents, 
pneumonia constitutes the sixth most common 
cause of death and the number one cause of 
death from infection [1]. Pneumonia can be 
particularly life-threatening in the elderly, patients 
with pre-existing cardiac or pulmonary conditions, 
in immunocompromised individuals, and in 
pregnant women [1]. 
Infections are the most common cause of 
morbidity and mortality in patients with malignant 
disorders, and in haematopoietic stem cell 
transplant (SCT) recipients, despite the use of 
infection prophylaxis, growth factors, and newer 
antimicrobial agents [2,3]. The main risk factors for 
development of infection in patients with malignant 
disorders include: uncontrolled malignancy, 
cytotoxic chemotherapy, immunosuppressive 
treatment, and immunological deficits, e.g. 
hypogammaglobulinaemia and T-cell depletion [4]. 
In this category of patients, the risk of infection is 
directly proportional to the intensity and duration of 
cytotoxic chemotherapy and immunosuppressive 
treatment [4]. 
 
Case Reports 
Case 1: A 17 years old Saudi female was 
diagnosed to have acute myeloid leukaemia 
(AML), M6 type, at King Faisal Specialist Hospital 
and Research Centre (KFSH&RC) in February 
2005. She presented with: fever, fatigue, mucosal 
bleeding, anaemia, thrombocytopenia, normal 
leucocytic count, few blasts on the blood film and 
40% blasts in the bone marrow but no palpable 
external lymphadenopathy or abdominal 
organomegaly. After receiving an ICE (idarubicin, 
cytozar and etoposide) induction course of 
chemotherapy, she achieved the first complete 
remission of her leukaemia. Thereafter, she 
received a consolidation course of chemotherapy 
composed of high dose   
cytosine arabinoside. On 22/5/2005, she received 
a non-myeloablative, allogeneic, peripheral blood 
SCT. The conditioning protocol consisted of: 
fludarabine and one session of total body 
irradiation. She was given prophylactic antibiotic 
therapy consisting of bactrim, penicillin and 
acyclovir.  In addition she received prophylaxis for 
graft versus host disease (GVHD) in the form of 
cyclosporine-A. The post-SCT course was 
complicated by acute GVHD of the colon, grade II, 
treated with steroids, cyclosporine-A, and 
tacrolimus;  Two episodes of CMV infections were 
treated with intravenous (IV) ganciclovir and 
reduced donor chimerism was managed with 
donor lymphocyte infusions. On 27/11/2006, the 
patient was readmitted with a two week history of 
low grade pyrexia and productive cough with 
yellowish sputum. Physical examination revealed 
reduced inspiratory volume with coarse crackles 
over the mid and lower lung fields bilaterally. 
Sputum culture grew beta-lactamase positive M. 
catarrhalis sensitive to certriaxone, ceftazidime, 
cefatoxime, and cefuroxime, but resistant to 
ampicillin and penicillin. Ziehl Neelsen stain and 
acid fast bacillus culture of the sputum were 
negative. Fungal cultures and aspergillus 
galactomannan test were also negative. 
Cytomegalovirus antigen test and shell vial were 
negative. Chest X ray (CXR) showed bilateral 
pulmonary infiltrates, more prominent on the left. 
Computerized tomography (CT) scan of the chest 
showed nodular infiltration involving the left lower 
lobe and the lateral segment of the right lower 
lobe (Figure 1). The patient was treated with IV 
ceftriaxone 2 grams per day for 5 days. She then 
received oral cefuroxime 500 mg twice daily for 10 
more days. Following discharge, she had routine 
follow up at the SCT clinic. On 18/12/2006, chest 
CT revealed complete resolution of nodular 
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pulmonary lesions. The patient was last seen at 
SCT clinic on 16/1/2007. She remained totally 
asymptomatic and physical examination confirmed 
her lung sounds were clear. Complete blood count 
(CBC) showed WBC: 7.74 x 10 
9/L, HB: 148 g/L, 
PLT: 247 x 10
9/L. The patient continued on 
tacrolimus and a tapered dose of prednisone in 
addition to prophylactic penicillin, bactrim and 
acyclovir. 
 
Case 2: A 50 year old Saudi male was 
diagnosed to have AML, M4 type, at KFSH&RC in 
early April, 2005. He presented with: recurrent 
perianal abscesses, elevated WBC count of 41 x 
10
9/L with myeloblasts on blood film, anemia, 
thrombocytopenia, and 80% blast cells on bone 
marrow biopsy, but no external, palpable 
lymphadenopathy and no palpable, abdominal 
organomegaly. Initially he received ICE induction 
chemotherapy but his leukemia was refractory to 
this so he was then given an FA (fludarabine and 
cytosine arabinoside) salvage course of 
chemotherapy which resulted in his first complete 
remission of leukemia. After controlling his AML, 
the patient was prepared for umbilical cord blood 
transplant (UCBT) since he had no compatible 
sibling donor. He received a pre-treatment protocol 
of IV busuphan and fludarabine. He was given 
prophylactic antibiotics consisting of bactrim, 
acyclovir, and penicillin as well as GVHD 
prophylaxis of IV methylprednisolone and 
cyclosporine-A. On 31/8/2005, the patient received 
an UCBT. Post-procedure, the patient developed a 
number of complications including: Klebsiella 
pneumoniae bacteremia and septic shock which 
were treated with IV meropenem and gentamicin. 
His fungal lung infection was treated with 
liposomal amphotericin-B (amBisome) and 
voriconazole.  His prolonged pancytopenia and 
delayed recovery of blood counts were managed 
with growth factor and granulocyte transfusions. 
On 6/12/2005, the patient was discharged from the 
SCT unit on cyclosporine-A. The chimerism study 
showed no engraftment, so treatment was 
continued with supportive measures [growth 
factors, packed red cell and platelet transfusions] 
for the low blood counts. In October2006, the 
patient was found to have a relapse of his AML. 
On 23/12/2006, he presented to the SCT clinic 
with a one week history of: fever, sore throat, and 
productive cough with yellow sputum. Physical 
examination revealed reduced inspiratory volume 
with crackles over middle and lower lung fields 
bilaterally. CXR showed radiological evidence of 
bronchopneumonia. Blood cultures were negative 
but sputum cultures revealed growth of beta-
lactamase, positive M. catarrhalis sensitive to 
ceforuxime, ceftazidime, cefotaxime and 
erythromycin, but resistant to penicillin and 
ampicillin. The patient received a five day course 
of IV ceftriaxone (two grams per day) at the 
oncology male treatment area. His treatement 
then was changed to oral cefuroxime 500 mg 
twice daily for one more week. Two weeks later, 
the patient was evaluated at the outpatient clinic. 
He was asymptomatic and physical examination 
showed his chest was clear.  Repeat CXR showed 
nearly complete resolution of the previous 
bronchopneumonic shadows. Thereafter, the 
patient remained clinically stable till he traveled to 
the USA in late January, 2007 for a second 
alternate donor SCT. 
 
Discussion 
Moraxella ( Branhamella)  catarrhalis (formerly 
called  Neisseria  or  Micrococcus catarrhalis) is a 
gram negative, anaerobic diplococcus frequently 
found as a commensal of the upper respiratory   
tract [5-8]. The organism was discovered and 
described in some detail more than a century ago 
[9]. However, M. catarrhalis has emerged as a 
human pathogen in the last decade [7,9]. 
Recently, M. catarrhalis is considered to be the 
third most common and most important cause of 
bronchopulmonary infections after Haemophilus 
influenzae and Streptococcus pneumoniae 
[10,11]. Risk factors for the development of M. 
catarrhalis infections and bacteremia include: 
advancced age; underlying chronic lung disorder 
e.g. bronchial asthma, chronic obstructive airway 
disease, alveolitis, and pulmonary fibrosis; 
pneumoconiosis and congenital lung disease; 
sickle cell disease and immunocompromised 
individuals e.g. HIV-positive patients, or those with 
agammaglobulinaemia, granulocytopenia and 
acute leukemia [5-17]. M. catarrhalis is linked to a 
variety of infections including upper and lower 
respiratory tract infections, bacteremia, septic 
complications, endocarditis, meningitis, and brain 
abscess in addition to wound infections [5-9,11-
14,16-18]. Invasive infection due to M. catarrhalis 
may occur in immunocompromised individuals but 
is uncommon [5,6,8,11,18]. M. catarrhalis can lead 
to community acquired as well as nosocomial 
infections [9,13,16,19]. M. catarrhalis can be 
isolated from blood, nasopharyngeal secretions, 
sputum, tracheal secretions, bronchoalveolar 
lavage, wound swabs, and tissue cultures e.g. 
endocardium [5,8,12-18,20,21]. Both of these 
patients were severely immunocompromized. Both 
had AML and were treated with two different forms 
of SCT. They had received cytotoxic 
chemotherapy and various immunosuppressive 
agents. Both infections were community acquired. 
Page 145   
Case Report   
www.ljm.org.ly
 
 
 
  Libyan J Med, AOP: 070424
 
The isolated organisms were cultured from sputum 
while blood cultures were negative in both 
patients. The lung infection in the initial patient 
was invasive and rather severe although the 
patient was not neutropenic at the time of the 
infection.  Bronchopneumonia occurred during a 
period of neutropenia and after the relapse of AML 
in the second patient. 
The first reported case of beta-lactamase 
production by M. catarrhalis was in 1976 [11]. 
Since that time, there has been a dramatic 
increase in the frequency of beta-lactamse 
production by this organism [11]. Today, 90% or 
more of the strains of M. catarrhalis  
are beta-lactamase producers [8-11,16,22]. 
Consequently when M. catarrhalis is considered to 
be the causative organism, the choice of an 
empiric antimicrobial therapy should be a beta-
lactamase resistant antibiotic [23]. The strains of 
M. catarrhalis are resistant to benzylpenicillin, 
ampicillin, amoxicillin and lincomycin and are 
usually susceptible to certain cephalosporins, 
macrolides, tetracyclines, and fluoroquinolones in 
addition to the combination of trimethoprim-
sulfamethoxazole [8-10,15,19,24]. Ceftriaxone has 
highly favorable pharmacokinetics which allow 
once daily dosing regimens to be employed even 
in the most severe infections associated with 
cancer therapy [25]. The overall mortality related 
to bacteremic pneumonia due to M. catarrhalis is 
about 13.3% despite the underlying disease [15]. 
Bacteremic pneumonia due to M. catarrhalis 
requires prompt treatment to prevent the 
development of serious organ complications such 
as endocarditis [18]. However, appropriate 
antimicrobial therapy can lead to clinical and 
microbiological cure in nearly all patients infected 
with this organism [13]. In these two patients, both 
isolates were beta-lactamase producers. Both 
were treated with IV ceftriaxone followed by oral 
cefuroxime. Obtaining necessary cultures and 
other required testing as well as early institution of 
appropriate antimicrobial therapy led not only to 
the resolution of pulmonary infiltrations but also to 
the prevention of further complications. 
Haematopoietic SCT is associated with 
pulmonary opportunistic infections and immune 
mediated responses that include idiopathic 
pneumonia syndrome and brochiolitis obliterans 
[26]. Pulmonary complications are the most 
common cause of death in SCT recipients. 
Unfortunately, the majority of these complications 
are not diagnosed antemortem [27]. As a 
consequence of underdiagnosis, SCT recipients 
may not receive appropriate therapy for a 
potentially treatable pulmonary complication [27]. 
Autopsy findings in recipients of allogeneic SCT 
and UCBT have shown that infectious 
complications are the causes of death in 
approximately 50% of deceased patients [27]. The 
dose-reduced conditioning regimens utilized in 
non-myeloablative SCT are associated with lower 
rates of pulmonary complications [26]. The use of 
steroid therapy in SCT has been shown to be a 
leading risk factor for infectious processes [28]. 
Recipients of allogeneic haematopoietic SCT have 
prolonged immunodeficiency that may extend 
beyond the first year post-SCT [29]. Depletion of 
T-cell used in mismatched SCT reduces the 
incidence of GVHD in graft recipients, but T-cell 
deficiency in these already extensively T-cell-
depleted patients may be an additional risk factor 
for infectious complications [30].  The 
reconstitution of immunity in SCT recipients is 
often delayed in adults, patients with extensive 
GVHD. and in T-cell depleted grafts [29]. 
However, the full reconstitution of the immune 
system in a recipient of hematopoietic SCT is one 
of the hallmarks of a successful graft [31].   
The first patient was expected to have a lower 
rate of infectious complications since she had 
received a nonmyeloablative allogeneic SCT. 
However, the development of GVHD and the use 
of various immunosuppressive agents 
predisposed this patient to an invasive lung 
infection despite having normal neutrophilic 
counts. The second patient had received an UCBT 
since he encountered serious complications 
before the autologous recovery of his blood counts  
and had not had a successful graft. His immunity 
continued to be depressed due to a relapse of his 
leukemia and since he was neutropenic at the 
time of the bronchopneumonia. 
 
 
Figure 1: CT scan of chest showing bilateral nodular 
pulmonary infiltration more prominent on the left side 
Conclusion 
M. catarrhalis can cause severe and invasive 
infections in immunocompromised individuals 
particularly patients with acute leukemia and 
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recipients of haematopoietic SCT who have been 
subjected to intensive cytotoxic chemotherapy and 
various immunosuppressive agents. Infections 
caused by this organism should be treated 
promptly in order to prevent sepsis and further 
complications. 
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